Hemab reports early sutacimig data and positive HMB-003 preclinical results

Hemab Therapeutics reported initial clinical results for sutacimig in two people with severe Factor VII deficiency. A single subcutaneous dose cut prothrombin time by more than half, while HMB-003 reduced severe bleeding days in a cynomolgus monkey model. Sutacimig is being studied in Phase 2b, and HMB-003 is in Phase 1 with initial clinical data expected in mid-2027.

The report provides an early human pharmacodynamic signal for Hemab's sutacimig program and preclinical support for its HMB-003 program. The programs remain clinical-stage, so their potential value depends on later clinical data and development progress.

  • 1Two participants with severe congenital Factor VII deficiency received one subcutaneous dose of sutacimig, after which prothrombin time shortened by more than half.
  • 2Sutacimig is being evaluated in a Phase 2b study, while HMB-003 is in a Phase 1 trial with initial clinical data expected in mid-2027.
  • 3In a cynomolgus monkey model, HMB-003 reduced the proportion of severe menstrual bleeding days and shifted bleeding toward lower intensity.
  • 4Hemab said the sutacimig and HMB-003 findings will be presented at the ASH Annual Meeting scheduled for December 12–15, 2026.
  • Only material 2 reports that one patient had a 5x increase in endogenous FVII(a) by Day 22; the broader materials do not provide that figure.

Sources